Comparison of the effects of captopril, tamoxifen and L-carnitine on renal structure and fibrosis after total unilateral ureteral obstruction in the rat

Scandinavian Journal of Urology and Nephrology

Volumn 41, Issue 2, 2007, Pages 91-97

  Shirazi, Mehdi ^a   Noorafshan, Ali ^b   Kroup, Mohsen ^a   Tanideh, Nader ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Captopril; L carnitine; Rat; Renal fibrosis; Stereology; Tamoxifen; Unilateral ureteral obstruction

Indexed keywords

CAPTOPRIL; CARNITINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLOMERULUS; HISTOPATHOLOGY; HYDRONEPHROSIS; KIDNEY BLOOD VESSEL; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY MEDULLA; KIDNEY SIZE; KIDNEY STRUCTURE; KIDNEY TUBULE; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOMETRY; URETER OBSTRUCTION;

ANIMALS; CAPTOPRIL; CARNITINE; FEMALE; FIBROSIS; KIDNEY; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; URETERAL OBSTRUCTION;

EID: 34247125262     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590600917974     Document Type: Article

References (32)

1. Klahr S. New insights into the consequences and mechanisms of renal impairment in obstructive nephropathy. Am J Kidney Dis 1991;18:689-99.
2. Klahr S. Obstructive uropathy. In: Schrier RW, editor. Renal and electrolyte disorders, 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2003. p. 520.
3. Nagle RB, Bulger RE. Unilateral obstructive nephropathy in the rabbit. II. Late morphologic changes. Lab Invest 1978; 38:270-8.
4. Hochberg D, Johnson CW, Chen J, Cohen D, Stern J, Vaughan ED Jr, et al. Interstitial fibrosis of unilateral ureteral obstruction is exacerbated in kidneys of mice lacking the gene for inducible nitric oxide synthase. Lab Invest 2000;80: 1721-8.
5. Kaneto H, Morrissey J, Klahr S. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993;44:313-21.
6. Wright EJ, McCaffrey TA, Robertson AP, Vaughan ED Jr, Felsen D. Chronic unilateral ureteral obstruction is associated with interstitial fibrosis and tubular expression of transforming growth factor-beta. Lab Invest 1996;74:528-37.
7. Furness PD 3rd, Maizels M, Han SW, Cohn RA, Cheng EY. Elevated bladder urine concentration of transforming growth factor-beta1 correlates with upper urinary tract obstruction in children. J Urol 1999;162:1033-6.
8. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 1994;45:1637-47.
9. Dedeoglu F, Rose CD, Athreya BH, Conard K, Grissom L, Magnusson M. Successful treatment of retroperitoneal fibrosis with tamoxifen in a child. J Rheumatol 2001;28: 1693-5.
10. De M, Jaap A, Dempster J. Tamoxifen therapy in steroidresistant Riedels disease. Scott Med J 2002;47:12-3.
11. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992;70:648-51.
12. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999;162:2003-5.
13. Mikulec AA, Hanasono MM, Lum J, Kadleck JM, Kita M, Koch RJ. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg 2001;3:111-4.
14. Panko WB, Beamon CR, Middleton GW, Gillenwater JY. Effect of obstruction of renal metabolism. Renal tissue metabolite concentration after alpha-ketoglutarate infusion. Invest Urol 1978;15:331-9.
15. Stecker JF Jr, Vaughan ED Jr, Gillenwater JY. Alteration in renal metabolism occurring in ureteral obstruction in vivo. Surg Gynecol Obstet 1971;133:846-8.
16. Nito H, Descoeudres C, Kurokawa K, Massry SG. Effect of unilateral obstruction on renal cell metabolism and function. J Lab Clin Med 1978;91:60-71.
17. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 2000;95:75-83.
18. Uhal BD, Gidea C, Bargout R, Bifero A, Ibarra-Sunga O, Papp M, et al. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol 1998;275:L1013-7.
19. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001;121:148-55.
20. Sener G, Paskaloglu K, Satiroglu H, Alican I, Kacmaz A, Sakarcan A, et al. L-carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol 2004;43:698-705.
21. Czerny B, Teister M, Juzyszyn Z, Modrzejewski A, Pawlik A. The effect of tamoxifen and fluoride on bone mineral density, biomechanical properties and blood lipids in ovariectomized rats. Basic Clin Pharmacol Toxicol 2004;95: 162-5.
22. Mouton PR, editor. Principles and practices of unbiased stereology. An introduction for bioscientists. Baltimore, MD: The Johns Hopkins University Press; 2002. p. 88-112.
23. Nyengaard JR. Stereologic methods and their application in kidney research. J Am Soc Nephrol 1999;10:1100-23.
24. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen KL, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988;96:379-94.
25. Sharma AK, Mauer SM, Kim Y, Michael AF. Interstitial fibrosis in obstructive nephropathy. Kidney Int 1993;44: 774-88.
26. Klahr S, Ishidoya S, Morrissey J. Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis 1995;26:141-6.
27. Mannisto TK, Karvonen KE, Kerola TV, Ryhanen LJ. Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen. J Hypertens 2001;19:1835-9.
28. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004;66:1774-84.
29. McDougal WS. Pharmacologic preservation of renal mass and function in obstructive uropathy. J Urol 1982;128:418-21.
30. Puce R, Porcaro AB, Curti P, Girelli D, Pantalena M, Malossini G, et al. Treatment of retroperitoneal fibrosis with tamoxifen: case report and review of literature. Arch Esp Urol 2000;53:184-90.
31. Owens LV, Cance WG, Huth JF. Retroperitoneal fibrosis treated with tamoxifen. Am Surg 1995;61:842-4.
32. Chambers JC, McGovern K. Tamoxifen for retroperitoneal fibrosis. Palliat Med 2005;19:163-4.